EP4784573A2 - Agents de ciblage fap dimériques comprenant une structure de base (4-quinoinolyl)glycinyl-2-cyanopyrrolidine, un groupe de liaison 1,3,5-triazine ou -triazinane, et un agent thérapeutique ou diagnostique pour le diagnostic ou le traitement des tumeurs - Google Patents
Agents de ciblage fap dimériques comprenant une structure de base (4-quinoinolyl)glycinyl-2-cyanopyrrolidine, un groupe de liaison 1,3,5-triazine ou -triazinane, et un agent thérapeutique ou diagnostique pour le diagnostic ou le traitement des tumeursInfo
- Publication number
- EP4784573A2 EP4784573A2 EP24777065.4A EP24777065A EP4784573A2 EP 4784573 A2 EP4784573 A2 EP 4784573A2 EP 24777065 A EP24777065 A EP 24777065A EP 4784573 A2 EP4784573 A2 EP 4784573A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino
- acid
- bis
- efap
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/04—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des agents de ciblage de FAP dimère ayant un noyau central comprenant une fraction 1,3,5-triazine ou un 1,3,5-triazinane. En particulier, l'invention concerne un composé, ou un sel pharmaceutiquement acceptable de celui-ci comprenant un noyau 1,3,5-triazine ou un noyau 1,3,5-triazinane qui est relié à deux fractions de liaison FAP par l'intermédiaire de lieurs L1 et L2, et à une charge utile par l'intermédiaire du lieur L3. La charge utile peut être un radio-isotope, un colorant fluorescent, un médicament cytotoxique ou similaire.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2023/050491 WO2024063648A1 (fr) | 2022-09-21 | 2023-09-21 | Plateforme et échafaudage pour agents de ciblage de fap |
| EP24165351 | 2024-03-21 | ||
| PCT/NL2024/050516 WO2025063849A2 (fr) | 2023-09-21 | 2024-09-23 | Agents de ciblage de fap dimère |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4784573A2 true EP4784573A2 (fr) | 2026-08-05 |
Family
ID=91248266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24777065.4A Pending EP4784573A2 (fr) | 2023-09-21 | 2024-09-23 | Agents de ciblage fap dimériques comprenant une structure de base (4-quinoinolyl)glycinyl-2-cyanopyrrolidine, un groupe de liaison 1,3,5-triazine ou -triazinane, et un agent thérapeutique ou diagnostique pour le diagnostic ou le traitement des tumeurs |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4784573A2 (fr) |
| WO (1) | WO2025063849A2 (fr) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011059586A2 (fr) * | 2009-10-30 | 2011-05-19 | The Regents Of The University Of Michigan | Petites molécules multifonctionnelles |
| JP2021500373A (ja) | 2017-10-23 | 2021-01-07 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤 |
| WO2019154859A1 (fr) | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Inhibiteur de fap |
| AU2019469641B2 (en) | 2018-11-13 | 2025-04-03 | Provincial Health Services Authority | Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders |
| PL3997103T3 (pl) | 2019-07-08 | 2025-03-24 | 3B Pharmaceuticals Gmbh | Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie |
| KR20220154111A (ko) | 2020-02-12 | 2022-11-21 | 필로켐 아게 | 표적 전달 적용들을 위한 섬유아세포 활성화 단백질 리간드들 |
| DE102021114711B4 (de) * | 2021-06-08 | 2023-11-02 | Medianezia GmbH | Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer |
| EP4342890A1 (fr) * | 2022-09-21 | 2024-03-27 | Erasmus University Rotterdam Medical Center | Plate-forme et échafaudage pour agents de ciblage fap |
-
2024
- 2024-09-23 EP EP24777065.4A patent/EP4784573A2/fr active Pending
- 2024-09-23 WO PCT/NL2024/050516 patent/WO2025063849A2/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025063849A2 (fr) | 2025-03-27 |
| WO2025063849A3 (fr) | 2025-05-08 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20260413 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |